

A P Bewley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7753035/publications.pdf>

Version: 2024-02-01

92
papers

2,124
citations

304743

22
h-index

265206

42
g-index

95
all docs

95
docs citations

95
times ranked

1727
citing authors

#	ARTICLE	IF	CITATIONS
1	Updating the diagnosis, classification and assessment of rosacea: recommendations from the global <scp>ROS</scp> acea <scp>CO</scp> nsensus (<scp>ROSCO</scp>) panel. British Journal of Dermatology, 2017, 176, 431-438.	1.5	177
2	The efficacy and safety of apremilast, etanercept and placebo in patients with moderate to severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). Journal of the European Academy of Dermatology and Venereology, 2017, 31, 507-517.	2.4	156
3	Delusional parasitosis: time to call it delusional infestation. British Journal of Dermatology, 2010, 163, 1-2.	1.5	125
4	Rosacea treatment update: recommendations from the global <scp>ROS</scp> acea <scp>CO</scp> nsensus (<scp>ROSCO</scp>) panel. British Journal of Dermatology, 2017, 176, 465-471.	1.5	122
5	Maximizing patient adherence for optimal outcomes in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 9-14.	2.4	114
6	Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids. British Journal of Dermatology, 2008, 158, 917-920.	1.5	102
7	Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 763-770.	2.4	73
8	Vitiligo is more than skin deep: a survey of members of the Vitiligo Society. Clinical and Experimental Dermatology, 2010, 35, 736-739.	1.3	62
9	Erythema of Rosacea Impairs Health-Related Quality of Life: Results of a Meta-analysis. Dermatology and Therapy, 2016, 6, 237-247.	3.0	53
10	Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1633-1643.	2.4	51
11	Delusional infestation and the specimen sign: a European multicentre study in 148 consecutive cases. British Journal of Dermatology, 2012, 167, 247-251.	1.5	50
12	Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2405-2410.	2.4	48
13	Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 397-402.	2.4	47
14	Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 816-827.	2.4	43
15	Patient perceptions of clear/almost clear skin in moderate to severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2200-2207.	2.4	42
16	Patients with delusional infestation (delusional parasitosis) often require prolonged treatment as recurrence of symptoms after cessation of treatment is common: an observational study. British Journal of Dermatology, 2011, 165, 893-896.	1.5	32
17	Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID-19 pandemic. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1666-1671.	2.4	30
18	Delusional infestation and patient adherence to treatment: an observational study. British Journal of Dermatology, 2013, 169, 607-610.	1.5	28

#	ARTICLE	IF	CITATIONS
19	Quimp (quality of life impairment): an addition to the quality of life lexicon. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e181-e182.	2.4	28
20	Psychodermatology services guidance: the report of the British Association of Dermatologists' Psychodermatology Working Party. British Journal of Dermatology, 2013, 168, 1149-1150.	1.5	27
21	Delusional parasitosis presenting as folie à trois: successful treatment with risperidone. British Journal of Dermatology, 2006, 155, 841-842.	1.5	26
22	Stigmatisation and body image impairment in dermatological patients: protocol for an observational multicentre study in 16 European countries. BMJ Open, 2018, 8, e024877.	1.9	26
23	Randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo: results of the HI-Light Vitiligo Trial*. British Journal of Dermatology, 2021, 184, 828-839.	1.5	25
24	Body dysmorphia in common skin diseases: results of an observational, cross-sectional multicentre study among dermatological outpatients in 17 European countries*. British Journal of Dermatology, 2022, 187, 115-125.	1.5	25
25	The neglected psychological aspects of skin disease. BMJ: British Medical Journal, 2017, 358, j3208.	2.3	24
26	Identifying key components for a psychological intervention for people with vitiligo – a quantitative and qualitative study in the United Kingdom using web-based questionnaires of people with vitiligo and healthcare professionals. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2275-2283.	2.4	22
27	Methods to improve quality of life, beyond medicines. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 318-328.	2.4	22
28	Management of patients with delusional parasitosis in a joint dermatology/ liaison psychiatry clinic. British Journal of Dermatology, 2009, 161, 197-199.	1.5	21
29	How to set up a psychodermatology clinic. Clinical and Experimental Dermatology, 2014, 39, 577-582.	1.3	20
30	Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1107-1115.	2.4	20
31	British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021*. British Journal of Dermatology, 2022, 186, 398-413.	1.5	20
32	A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque psoriasis treated with biologics in a REAL world setting (PSO-BIO-REAL). Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2566-2573.	2.4	19
33	An international study of the prevalence of substance use in patients with delusional infestation. Journal of the American Academy of Dermatology, 2017, 77, 778-779.	1.2	18
34	Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1614-1621.	2.4	18
35	Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT. Health Technology Assessment, 2020, 24, 1-128.	2.8	18
36	Quality of life measurement in occupational skin diseases. Position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Occupational Skin Disease. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1924-1931.	2.4	17

#	ARTICLE	IF	CITATIONS
37	A study of service provision in psychocutaneous medicine. <i>Clinical and Experimental Dermatology</i> , 2014, 39, 13-18.	1.3	16
38	Delusional infestation may be caused by recreational drug usage in some patients, but they may not disclose their habit. <i>Clinical and Experimental Dermatology</i> , 2017, 42, 41-45.	1.3	16
39	Longer Duration of Untreated Psychosis is Associated with Poorer Outcomes for Patients with Delusional Infestation. <i>Acta Dermato-Venereologica</i> , 2018, 98, 848-854.	1.3	16
40	Characterizing high-burden rosacea subjects: a multivariate risk factor analysis from a global survey. <i>Journal of Dermatological Treatment</i> , 2020, 31, 168-174.	2.2	15
41	Managing patients with delusional infestations in an integrated psychodermatology clinic is much more cost-effective than a general dermatology or primary care setting. <i>British Journal of Dermatology</i> , 2017, 177, 544-545.	1.5	14
42	Delusional infestation with unusual pathogens: a report of three cases. <i>Clinical and Experimental Dermatology</i> , 2011, 36, 745-748.	1.3	13
43	Development of hidradenitis suppurativa in a patient treated with ustekinumab for her psoriasis: A potential paradoxical reaction?. <i>Dermatologic Therapy</i> , 2018, 31, e12742.	1.7	13
44	The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 213-221.	2.2	13
45	Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL). <i>Dermatology and Therapy</i> , 2020, 10, 1099-1109.	3.0	13
46	Assessing and Improving Psychological Well-Being in Psoriasis: Considerations for the Clinician. <i>Psoriasis: Targets and Therapy</i> , 2022, Volume 12, 25-33.	2.2	13
47	Morgellons disease: experiences of an integrated multidisciplinary dermatology team to achieve positive outcomes. <i>Journal of Dermatological Treatment</i> , 2018, 29, 208-213.	2.2	12
48	Psychological and professional impact of COVID-19 lockdown on French dermatologists: Data from a large survey. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 101-105.	1.0	12
49	Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 403-412.	2.4	10
50	Mental health and dermatology practice in the COVID-19 pandemic. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 816-817.	1.3	9
51	Chronic urticaria in the real-life clinical practice setting in the UK: results from the noninterventional multicentre AWARE study. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 1003-1010.	1.3	9
52	Identifying the best predictive diagnostic criteria for psoriasis in children (< 18 years): a UK multicentre case-control diagnostic accuracy study (DIPSOC study)*. <i>British Journal of Dermatology</i> , 2022, 186, 341-351.	1.5	9
53	Quality of life assessment in core outcome sets: A position statement of the EADV Task Force on Quality of Life and Patient Oriented Outcomes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 20-23.	2.4	9
54	An ethnographic study into the psychological impact and adaptive mechanisms of living with hand eczema. <i>Clinical and Experimental Dermatology</i> , 2015, 40, 495-501.	1.3	8

#	ARTICLE	IF	CITATIONS
55	Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries. <i>Journal of Dermatological Treatment</i> , 2020, 32, 1-8.	2.2	8
56	Current application of National Institute for Health and Clinical Excellence (NICE) guidance in the management of patients with severe psoriasis: a clinical audit against NICE guidance in seven National Health Service specialist dermatology units in Engla. <i>Clinical and Experimental Dermatology</i> , 2011, 36, 602-606.	1.3	7
57	Erythema elevatum diutinum associated with loss of the uvula. <i>JAAD Case Reports</i> , 2017, 3, 212-214.	0.8	7
58	Atypical variant of trigeminal trophic syndrome successfully treated with pregabalin: a case report series. <i>Clinical and Experimental Dermatology</i> , 2019, 44, 225-228.	1.3	7
59	An analysis of qualitative responses from a UK survey of the psychosocial wellbeing of people with skin conditions and their experiences of accessing psychological support. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 37-42.	1.3	7
60	Idiopathic delusional infestation: an observational study. <i>British Journal of Dermatology</i> , 2016, 175, 800-802.	1.5	6
61	Dysaesthetic penoscrotodynia may be a somatoform disorder: results from a two-centre retrospective case series. <i>Clinical and Experimental Dermatology</i> , 2016, 41, 474-479.	1.3	6
62	Burnout in psychodermatology: results from a European survey. <i>British Journal of Dermatology</i> , 2020, 183, 1107-1108.	1.5	6
63	An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the H&Light Vitiligo Trial)*. <i>British Journal of Dermatology</i> , 2021, 184, 840-848.	1.5	6
64	Real-World Experience Using Topical Therapy Calcipotriol and Betamethasone Dipropionate Foam in Adults with Beyond-Mild Psoriasis. <i>Dermatology and Therapy</i> , 2021, 11, 555-569.	3.0	6
65	UK psychodermatology services in 2019: service provision has improved but is still very poor nationally. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1046-1051.	1.3	6
66	Delusional infestation carries an increased mortality risk: a report of two cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2261-2262.	2.4	5
67	Efficacy, quality of life, and treatment satisfaction: an indirect comparison of calcipotriol/betamethasone dipropionate cream versus foam for treatment of psoriasis. <i>Current Medical Research and Opinion</i> , 2022, 38, 1521-1529.	1.9	5
68	Olfactory reference syndrome (ORS) successfully treated with a selective serotonin reuptake inhibitor. <i>Clinical and Experimental Dermatology</i> , 2017, 42, 937-938.	1.3	4
69	Are dermatologists who treat patients with delusional infestation at risk of major complaints and being stalked?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e379-e381.	2.4	4
70	Cost-effectiveness of apremilast in moderate to severe psoriasis in the United Kingdom. <i>Cogent Medicine</i> , 2018, 5, 1495593.	0.7	4
71	A patient with delusional infestation by proxy: Issues for vulnerable adults. <i>Dermatologic Therapy</i> , 2018, 31, e12724.	1.7	4
72	An evaluation of intensity of delusional belief in patients with delusional infestation pre- and post-treatment in a specialist psychodermatology center. <i>Journal of Dermatological Treatment</i> , 2020, 31, 602-605.	2.2	4

#	ARTICLE	IF	CITATIONS
73	Beyond-Mild Psoriasis: A Consensus Statement on Calcipotriol and Betamethasone Dipropionate Foam for the Topical Treatment of Adult Patients. <i>Dermatology and Therapy</i> , 2021, 11, 1791-1804.	3.0	4
74	Calcipotriol/betamethasone dipropionate aerosol foam in the treatment of psoriasis: new perspectives for the use of an innovative topical treatment from real-life experience. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 212-219.	0.8	4
75	Tertiary syphilis and Kaposi sarcoma mistaken for systemic sarcoidosis in an HIV-negative patient. <i>British Journal of Dermatology</i> , 2015, 173, 1501-1504.	1.5	3
76	Western herbal medicine is a useful adjunct to traditional dermatological practice. <i>Clinical and Experimental Dermatology</i> , 2018, 43, 58-60.	1.3	3
77	Dose increase beyond labelled dose of biologics is associated with incremental pharmacy costs: results from a real-world study in the UK. <i>Journal of Dermatological Treatment</i> , 2019, 30, 376-382.	2.2	3
78	Ocular toxoplasmosis in a patient treated with ustekinumab for psoriasis. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 802-804.	1.3	3
79	Selection process of measures for core outcome set should utilize the highest methodology level and should be maximally free of bias. Comment on "IDQoL, CDLQI and the 45-item CADIS received a sufficient content validity rating during the HOME VII meeting in Japan: a group discussion study". <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e208-e209.	2.4	3
80	Systemic sarcoidosis reactions as a result of tumour necrosis factor- α treatment for patients with psoriasis. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1548-1550.	1.3	3
81	Patients with nodular prurigo commonly have pre-existing psychological disease that requires treatment concomitant with cutaneous therapies. <i>British Journal of Dermatology</i> , 2021, 185, 1258-1259.	1.5	3
82	Dermatitis artefacta in childhood and adolescence: a spectrum of disease. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 525-534.	0.2	3
83	A difficult case of dermatitis artefacta requiring surgical intervention. <i>British Journal of Dermatology</i> , 2013, 168, 889-891.	1.5	2
84	Adolescent "Saxophone Penis" Secondary to Crohn's Disease: Misdiagnosed as Being Posttraumatic. <i>Pediatric Dermatology</i> , 2016, 33, e14-5.	0.9	2
85	Cutaneous lupus erythematosus is strongly associated with psychiatric disease. <i>British Journal of Dermatology</i> , 2016, 174, 958-959.	1.5	2
86	Habit reversal therapy quickly and significantly contributes to the management of children with atopic eczema. <i>British Journal of Dermatology</i> , 2018, 178, 584-585.	1.5	2
87	Psychodermatological research priorities identified by Priority Setting Partnerships. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 1106-1108.	1.3	2
88	Exploring patient-physician trust dynamics in patients with psychocutaneous and general dermatological disease. <i>British Journal of Dermatology</i> , 2021, 184, 568-570.	1.5	1
89	19th Congress of the European Society for Dermatology and Psychiatry (ESDaP) and 2nd Brain Skin Colloquium Conference (BSC), 11-13 June 2021, London. <i>Acta Dermato-Venereologica</i> , 2021, , .	1.3	1
90	Meeting the psychological needs of dermatology patients. <i>British Journal of Dermatology</i> , 2017, 176, 858-859.	1.5	0

#	ARTICLE	IF	CITATIONS
91	sQuiz your knowledge: Extensive facial scarring; an unusual presentation in a neuropsychiatric patient. <i>European Journal of Dermatology</i> , 2017, 27, 451-452.	0.6	0
92	A changed life: the life experiences of patients with psoriasis receiving biological treatment. <i>British Journal of Dermatology</i> , 2021, 184, 580-580.	1.5	0